Laurion Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-700,000
Closed -$37.8M 377
2025
Q4
$37.8M Buy
+700,000
New +$33.7M 1.41% 19
2024
Q2
Sell
-50,000
Closed -$2.71M 572
2024
Q1
$2.71M Sell
50,000
-331,300
-87% -$16.9M 0.02% 317
2023
Q4
$19.6M Hold
381,300
0.17% 119
2023
Q3
$22.1M Sell
381,300
-350,000
-48% -$21.4M 0.14% 135
2023
Q2
$46.8M Buy
731,300
+600,000
+457% +$40.2M 0.26% 90
2023
Q1
$9.1M Buy
+131,300
New +$9.26M 0.06% 201
2022
Q4
Sell
-500,000
Closed -$35.5M 425
2022
Q3
$35.5M Sell
500,000
-390,000
-44% -$28.3M 0.21% 100
2022
Q2
$68.5M Buy
+890,000
New +$67.8M 1.06% 19
2022
Q1
Sell
-9,000
Closed -$561K 548
2021
Q4
$561K Sell
9,000
-69,000
-88% -$4.05M 0.01% 407
2021
Q3
$4.62M Buy
+78,000
New +$5.14M 0.02% 351
2020
Q3
Sell
-69,200
Closed -$4.07M 851
2020
Q2
$4.07M Sell
69,200
-153,700
-69% -$9.19M 0.05% 246
2020
Q1
$12.4M Buy
222,900
+32,900
+17% +$2.01M 0.14% 150
2019
Q4
$12.2M Sell
190,000
-257,500
-58% -$14.7M 0.09% 193
2019
Q3
$22.7M Buy
+447,500
New +$21M 0.17% 134
2018
Q4
Sell
-750,100
Closed -$46.6M 1121
2018
Q3
$46.6M Buy
+750,100
New +$44.5M 0.45% 27
2017
Q4
Sell
-77,500
Closed -$4.94M 1541
2017
Q3
$4.94M Sell
77,500
-89,500
-54% -$5.23M 0.02% 515
2017
Q2
$9.3M Buy
167,000
+110,100
+193% +$5.99M 0.05% 337
2017
Q1
$3.1M Buy
56,900
+54,800
+2,610% +$3.01M 0.02% 520
2016
Q4
$123K Buy
+2,100
New +$115K ﹤0.01% 1046
2016
Q2
Sell
-600,000
Closed -$38.3M 826
2016
Q1
$38.3M Buy
+600,000
New +$37.8M 0.61% 38
2015
Q4
Sell
-80,000
Closed -$4.74M 883
2015
Q3
$4.74M Buy
+80,000
New +$5.08M 0.06% 250
2014
Q3
Sell
-580,000
Closed -$28.1M 302
2014
Q2
$28.1M Buy
580,000
+245,000
+73% +$12.1M 0.59% 50
2014
Q1
$17.4M Buy
335,000
+301,800
+909% +$16.1M 0.64% 57
2013
Q4
$1.76M Sell
33,200
-81,900
-71% -$4.17M 0.06% 118
2013
Q3
$5.33M Buy
+115,100
New +$5.05M 0.39% 70

Other funds holding BMY

Laurion Capital Management's BMY Position: Q1 2026 in Review

Laurion Capital Management opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 36,100 shares worth $2.19M. The stake represents 0.1% of the portfolio and ranks #202 among its holdings. This is a return to the name: Laurion Capital Management previously reported a position in BMY as recently as Q2 2024.

Laurion Capital Management first reported a position in BMY in Q3 2013 and has held it in 26 quarters since. The position peaked at $176M in Q1 2020. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Laurion Capital Management held 36,100 shares of Bristol-Myers Squibb worth $2.19M as of Q1 2026.
  • Bristol-Myers Squibb was a new Laurion Capital Management position in Q1 2026.
  • Bristol-Myers Squibb made up 0.1% of Laurion Capital Management's portfolio in Q1 2026, its #202 holding.
  • Laurion Capital Management first reported a position in Bristol-Myers Squibb in Q3 2013 and has held it in 26 quarters since.
  • Laurion Capital Management's Bristol-Myers Squibb position peaked at $176M in Q1 2020.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Laurion Capital Management's 13F filing for Q1 2026, filed 14 May 2026.